Novel Therapies Active in Head and Neck Cancers
(MedPage Today) -- Three-fourths of patients with advanced non-melanoma skin cancer of the head and neck achieved disease control with the oncolytic virus RP1 plus the PD-1 inhibitor nivolumab (Opdivo), a preliminary clinical trial showed.
The...
Source: MedPage Today Radiology - Category: Radiology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Head and Neck Cancer | Melanoma | Nonmelanoma Skin Cancer | Radiology | Skin | Skin Cancer